Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

  • There is currently no data for IQAI

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: AIQ revenue soars; Mobius Investment net assets drop

Tue, 28th Feb 2023 19:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

AIQ Ltd - Cayman Islands-based firm focused on acquiring and developing e-commerce sector businesses - Revenue in the year that ended October 31 multiplies to GBP498,388 from GBP61,863 the year prior. Pretax loss narrows to GBP640,906 from GBP1.2 million. Attributes this primarily to the delivery of the DeFi DEX contract, which accounted for GBP438,824 of revenue. "We entered the year having decided to pivot to focus on the provision of IT consultancy services to customers who deliver blockchain technology and digital assets, such as NFTs. We had some success during 2022 in capitalising on the lack of IT solutions providers in Asia that specialise in the delivery of blockchain platforms, including forming partnerships with key solutions providers and completing a contract to project manage the supply of a decentralised finance exchange to a customer based in Australia," Chair Harry Chathli comments.

----------

Mobius Investment Trust PLC - investment company - Net asset value per share stands at 134.2 pence as at November 30, down 13% from 153.4p on the same date a year prior. Share price as at November 30 falls 15% to 131.0 pence from 154.5p on the same date a year before. Notes how unprecedented the year has been in terms of political and economic events, with the war in Ukraine and China's hard stance on Covid-19 pushing the recovery back. Records a total NAV return of 12.3%. Declares a final dividend of 1.20p, up sharply from 0.35p.

----------

IQ-AI Ltd - Jersey-based medical services firm - Says gallium maltolate, a novel oral agent, was granted orphan drug designation by the US Food & Drug Administration for the treatment of glioblastoma multiforme brain cancer. Intends to "take full advantage" of the benefits orphan designation offers. This includes assistance in the drug development process, tax credits, grant opportunities, and seven years of market exclusivity post-approval. Notes that the status is independent from the overall approval process by the FDA.

----------

Kazera Global PLC - diamond and rare earths explorer in South Africa and Namibia - Says it will not be able to publish its annual report and accounts for the year that ended June 30 at the end of February. Says that trading on AIM will continue to be suspended until the publication of the results. Continues to make progress with its heavy mineral sands and diamond operations now in production. Confirms that it has paid off all outstanding debt to the former directors and loan providers and now sits in a healthy net cash position.

----------

Uru Metals Ltd - Toronto-based investor and mine project developer - Says Richard Montjoie was appointed as interim Chief Executive of Zeb Nickel. Says he has been with Zeb for over a decade. Adds that he played a pivotal role in the exploration efforts that have led to the discovery of several nickel deposits. Uru has just shy of 75% stake in Zeb Nickel.

----------

Appreciate Group PLC - Merseyside, England-based multi-retailer redemption product provider to corporate and consumer markets - Says it takeover by Paypoint PLC is complete, as the court-sanctioned the scheme of arrangement between Appreciate and relevant Appreciate shareholders. PayPoint agreed to buy Appreciate in a deal which valued the company at around GBP83 million. PayPoint will pay 33 pence in cash and 0.019 of a new PayPoint share for each Appreciate share.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Agrees on new terms with its lending banks for in a second amendment and restatement to its loan agreement for both aircraft loans. Fixes interest rates for tranche 1 and tranche 2 for DP Aircraft III tranche 1 at 5.26% and tranche 2 at a fixed balloon interest rate of 6.61%. Fixes DP Aircraft IV tranche 1 at 5.42% and tranche 2 at a fixed balloon interest rate of 6.89%. Says that the aggregated final balloon payment in 2026 is forecast to amount to approximately USD69.5 million based on the new terms.

----------

Hambro Perks Acquisition Co Ltd - Hambro Perks-sponsored special purpose acquisition vehicle - Says 93% of its shareholders approved the extension the business combination deadline to November 30. "We are delighted to have received shareholder approval for the extension, which highlights the confidence and support of our investors. We are encouraged by the positive conversations we are having with interested companies for a possible business combination and look forward to updating the market in due course," Chief Executive Dominic Perks comments.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 May 2025 13:28

IN BRIEF: IQ-AI applies for breakthrough therapy designation for GaM

IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the US Food & Drug Administration for its oral gallium maltolate therapy. Its phase 1 trial is evaluating the therapy as a potential treatment for adult patients with recurrent or refractory glioblastoma IDH-wildtype, with preliminary findings suggesting an overall survival of 34.1 months from initial diagnosis. This significantly exceeds the median survival of 14 to 15 months reported for patients undergoing standard treatment, though IQ-AI notes that caution is appropriate when considering the results due to the size of the trial population. The FDA is required to respond to IQ-AI's application within 60 days.

Read more
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
16 Aug 2024 20:40

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.